Trial reportHernia : the journal of hernias and abdominal wall surgery2025
Cessation vs. no cessation of acetylsalicylic acid preoperatively in laparoscopic totally extraperitoneal inguinal hernia repair (CAPTAIN): interim report from a multicentre, single-blind, randomised controlled trial.
Trial report in Hernia : the journal of hernias and abdominal wall surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Definition, analysis, reporting, and interpretation of perioperative bleeding in randomized controlled trials: a methodological systematic review.Perioperative medicine (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the increasing prevalence of antiplatelet agent use and the lack of high-quality evidence, the CAPTAIN trial aimed to investigate the safety and provide recommendations on continuing acetylsalicylic acid perioperatively in patients undergoing elective laparoscopic totally extraperitoneal inguinal hernia repair (LIHR).
methodsThe CAPTAIN trial was a multicentre, surgeon blind, randomized controlled trial conducted from April 2016 to April 2023. Patients undergoing LIHR were eligible for inclusion. Participants were randomized to either the acetylsalicylic acid cessation group or the continued acetylsalicylic acid group. The primary endpoint was the incidence of hematoma formation at discharge.
resultsAfter a total of 69 patients were randomized, four patients dropped out, leaving 35 patients in the acetylsalicylic acid cessation group and 30 in the continued acetylsalicylic acid group. The baseline characteristics of both groups were similar. While the distribution of hernia types was largely comparable, there were significantly more direct inguinal hernias in the continued acetylsalicylic acid group (p < 0.001). The primary outcome, hematoma formation at discharge, was similar between groups (3.3% vs. 2.9%, p = 1.000). Secondary outcomes, including wound bruising, post-discharge hematomas, pain, seroma formation, wound infection rates, and length of hospital stay, did not differ significantly between groups. No thromboembolic complications, readmissions, chronic pain, or recurrences were observed during follow-up in either group.
conclusionThis study found that it is safe to continue acetylsalicylic acid perioperatively in selected patients undergoing LIHR without an increased risk of complications.
Indexed as
Identifiers
39847106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.